Entrada Therapeutics【TRDA】銘柄情報

Entrada Therapeutics Inc (TRDA) 銘柄情報

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

プレミアム

通貨

6.37

( - )

買値

5.55

売値

7.10

出来高

0.00 日の範囲 0.00

4.93 52 週間の範囲 16.45

時価総額

229.534M

前日終値

6.37

始値

時刻

5.6

最終取引時間

20:31:12

財務取引量

VWAP

平均取引量 (3 か月)

US$ 362,324

発行済株式数

36,033,548

配当利回り

PER

-1.65

1 株当たり利益 (EPS)

-3.99

歳入

5.74M

純利益

-166.12M

Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company’s Endosomal Escape Vehicle, therapeutic candidates a... Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company’s Endosomal Escape Vehicle, therapeutic candidates are based on a novel therapeutic; a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases. Its preclinical product includes ENTR-601-44; ENTR-601-45; and VX-670. The company was formerly known as CycloPorters, Inc., and changed its name to Entrada Therapeutics, Inc., in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts. 詳細を表示

セクター

Healthcare

業界

Biotechnology & Life Sciences

ウェブサイト

www.entradatx.com

本社

Boston, United States

設立

2026

Entrada Therapeutics Inc is listed in the Healthcare sector of the ナスダック市場 with ticker TRDA. The last closing price for Entrada Therapeutics was US$6.37. Over the last year, Entrada Therapeutics shares have traded in a share price range of US$ 4.93 to US$ 16.45.

Entrada Therapeutics currently has 36,033,548 shares in issue. The market capitalisation of Entrada Therapeutics is US$229.53 million. Entrada Therapeutics has a price to earnings ratio (PE ratio) of -1.65.

Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 mg/kg in Entrada Therapeutics’ ELEVATE-45-201 Study

-- Participants in Cohort 1 have progressed to the open-label, Phase 2 portion of ELEVATE-45-201 -- -- Company...

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, June 01, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that the...

Form 4 - Statement of changes in beneficial ownership of securities

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Entrada Therapeutics Reports First Quarter 2026 Financial Results

-- Announced positive ELEVATE-44-201 Cohort 1 topline results in Duchenne muscular dystrophy showing favorable...

Entrada Therapeutics Announces Positive Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study

-- Achieved the primary objective with favorable safety and tolerability, no discontinuations and no serious...

Entrada Therapeutics to Announce Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study on May 7, 2026

BOSTON, May 06, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) will announce topline...

Form 4 - Statement of changes in beneficial ownership of securities

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	-0.68	-9.64539007092	7.05	7.14	6.34	250134	6.71471291	CS
4	-0.59	-8.47701149425	6.96	7.52	5.63	451690	6.70747763	CS
12	-6.565	-50.7537688442	12.935	16.45	5.63	366900	9.05076429	CS
26	-3.98	-38.4541062802	10.35	16.45	5.63	286151	9.91686125	CS
52	-2.1	-24.7933884298	8.47	16.45	4.93	261266	8.37654783	CS
156	-8.01	-55.702364395	14.38	21.79	4.93	157755	10.98691832	CS
260	-20.13	-75.9622641509	26.5	36.85	4.93	133920	12.03698814	CS